Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Insights into the Cellular and Molecular Mode of Action behind the Anti-Fibrotic Effects of Nerandomilast

ABSTRACT: Insights into the Cellular and Molecular Mode of Action behind the Anti-Fibrotic Effects of Nerandomilast

PROVIDER: PRJNA1134254 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR29770600_1.fastq.gz	Fastqsanger.gz
	SRR29770600_2.fastq.gz	Fastqsanger.gz
	SRR29770601_1.fastq.gz	Fastqsanger.gz
	SRR29770601_2.fastq.gz	Fastqsanger.gz
	SRR29770602_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 84

Similar Datasets

Insights into the Cellular and Molecular Mode of Action behind the Anti-Fibrotic Effects of Nerandomilast

Project description:The quest for innovative pharmacologic interventions in idiopathic pulmonary fibrosis (IPF) is a challenging journey. The complexity of the disease demands a comprehensive approach that targets multiple cell types and pathways. In this study, we explored the anti-fibrotic properties of nerandomilast, a preferential phosphodiesterase 4B inhibitor, focusing on its effects on myofibroblasts (MFs) and endothelial cells. Our findings demonstrate that nerandomilast induces the dedifferentiation of human lung MFs and diminishes their contractility in vitro by interfering with TGFβ and GPCR signaling pathways. Moreover, nerandomilast effectively mitigates features of vascular dysfunction, such as increased vascular permeability and immune cell infiltration, both in vitro and in vivo. This is accomplished by strengthening endothelial junctions and inhibiting the expression of adhesion molecule proteins. Furthermore, in a rat model of bleomycin-induced pulmonary fibrosis, nerandomilast normalizes the specialization of endothelial cell types. The results of this study significantly contribute to the growing knowledge around the potential therapeutic use of nerandomilast in the treatment of IPF by providing valuable insights into its cellular and molecular mode of action

2025-04-28 | GSE271994 | GEO

Novel insights into the mode of action of 1,4 dioxane

Project description:Novel insights into the mode of action of 1,4 dioxane

| PRJNA663909 | ENA

Praziquantel mode of action and resistance

Project description:Praziquantel mode of action and resistance

| PRJEB1281 | ENA

Praziquantel mode of action and resistance

Project description:This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/The drug Praziquantel is the most commonly used drug for parasitic flatworms. It is currently being increasingly used in mass drug administration programmes, raising concerns over whether resistance will develop. Although widely used, its mode of action was until very recently uncertain. This study will investigate the praziquantel mode of action and resistance by sequencing the transcriptomes of Dugesia japonica and different stages and strains of S. mansoni.

2013-05-13 | E-ERAD-135 | biostudies-arrayexpress

Linking toxicant physiological mode of action with induced gene expression changes in Caenorhabditis elegans

Project description:This SuperSeries is composed of the following subset Series: GSE21008: Linking toxicant physiological mode of action with induced gene expression changes in Caenorhabditis elegans: atrazine GSE21010: Linking toxicant physiological mode of action with induced gene expression changes in Caenorhabditis elegans: cadmium GSE21011: Linking toxicant physiological mode of action with induced gene expression changes in Caenorhabditis elegans: fluoranthene Refer to individual Series

2010-03-23 | E-GEOD-21012 | biostudies-arrayexpress

Mode of action studies with DNDi6174 in Leishmania donovani

Project description:Mode of action studies with DNDi6174 in Leishmania donovani

| PRJEB45584 | ENA

Antibacterial mode of action of alpha-mangostin on Staphylococcus epidermidis

Project description:Antibacterial mode of action of alpha-mangostin on Staphylococcus epidermidis

| PRJNA450895 | ENA

Identifying the molecular mode of action of itraconazole in colorectal cancer

Project description:Two cell lines (HT55 and SW948) were found responsive to itraconazole treatment. To identify the mode of action cells were treated with itraconazole or control (DMSO) and then subjected to RNAseq analysis once the phenotype had developed

2018-05-21 | GSE114013 | GEO

Antibacterial mode of action of alpha-mangostin on Staphylococcus epidermidis

Project description:Alpha-mangostin (α-MG) is a natural xanthone reported to exhibit rapid bactericidal activity against Gram-positive bacteria, and may therefore have potential clinical application in healthcare sectors. This study sought to identify the antibacterial mode of action of α-MG against Staphylococcus epidermidis RP62A through RNA-sequencing technology.

2018-04-19 | GSE113302 | GEO

Exploring the mode of action of anti-mycobacterial activity of C17 diynes using microarray

Project description:The anti-mycobacterial activity of C17 diynes has been described previously, however, their mode of action remains unknown. Microarray techniques were used to explore the genetic regulation reponses of Mycobacterium smegmatis to treatment with the C17 diynes, falcarinol and panaxydol. Our analyses showed a distinct mode of action of the C17 diynes when compared with commonly used anti-mycobacterial drugs. In addition, geneset enrichment analysis, pathway enrichment analysis and PASS analysis revealed significant gene ontology terms, pathways and potential modes of action, respectively. Combing the results of the three analyses, we hypothesize that the C17 diynes inhibit fatty acid biosynthesis, specifically phospholipid synthesis in mycobacteira.

2015-02-23 | GSE64323 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data